MSD announces the Primary Results of Trial uating Cardiovascular Outcomes with Sitagliptin
MSD, known as Merck in the United States and Canada, has announced the primary results of the Trial uating Cardiovascular […]
Say something
Tags: American Diabetes Association, Anti-diabetic medication, Canada, Cardiovascular disease, diabetes, Diabetic Medicine and Diabetes Trials Unit, Dipeptidyl peptidase-4 inhibitors, Director, Duke Clinical Research Institute, Health/Medical/Pharmaceuticals, Heart Failure, II diabetes, JANUVIA, medicine, Merck & Co, Merck Research Laboratories, New England Journal, nonfatal myocardial infarction, nonfatal stroke, Organofluorides, Pharmaceutical industry, Pharmacology, President, professor, Roger M. Perlmutter, Rury Holman, Sitagliptin, study co-chair, the New England Journal of Medicine, United States, University of Oxford, unstable angina
-
-
Flipkart Health+ App Launched
06-04-2022
